Name: Salivary Gland Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH5455
Price: 4350 USD
Availability: InStock

Salivary Gland Cancer Treatment Market Share Size Trends Growth 2023-30

Salivary Gland Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Salivary Gland Cancer Treatment Market is Segmented By Type (Mucoepidermoid Carcinoma, Adenoid Cystic Carcinoma, Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma), Polymorphous adenocarcinoma, Pleomorphic Adenoma, Warthin&rsquo;s Tumor, Others), By Diagnosis (Physical exam, Imaging tests, Magnetic resonance imaging (MRI), Computerized tomography (CT), Positron emission tomography (PET), Ultrasound, Others, Biopsy, Others), By Treatment (Surgery, Radiation therapy, Chemotherapy, Cisplatin, Mitoxantrone, Doxorubicin (Adriamycin), Epirubicin (Ellence), Cyclophosphamide (Cytoxan), Paclitaxel (Taxol), Docetaxel (Taxotere), Vinorelbine (Navelbine), Methotrexate, Supportive (palliative) care, Others), By End-User (Hospital, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029.</h2>

Salivary Gland Cancer Treatment Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029). Salivary gland cancer is rare cancer that develops in the tissue of the salivary glands. These glands control the production of saliva. A lump or difficulty swallowing are indications of this malignancy. Most salivary gland cancers begin in the parotid glands and are benign. Biopsy or imaging tests such as an MRI, CT scan, or PET scan diagnose this illness. Salivary gland tumors are often treated with surgery to remove the tumor. Additional treatments, such as radiation therapy and chemotherapy, may be required for people with salivary gland cancer.

<h3>Salivary Gland Cancer Treatment Market Dynamics</h3>

Increasing clinical trials and product launches by the market players are expected to drive market growth.

The Ministry of Health, Labour and Welfare (MHLW) approved Chugai Pharmaceutical Co., Ltd.&#39;s anti-HER2 humanized monoclonal antibody Herceptin Injection 60 and 150 [generic name: trastuzumab] for the additional indication of advanced or recurrent HER2-positive salivary gland cancer not amenable to curative resection on November 25, 2021. The MHLW approved orphan drug classification for this indication on March 11, 2021. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The high cost of treatment, lack of awareness about the disorder, side effects caused by the drugs and limited availability of required healthcare facilities are factors the market is expected to get hampered in the forecast period.

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic has moderately impacted the healthcare industry. The oral mucosal and salivary gland cells are known targets for directly replicating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of the virus in saliva is a source of transmission of the infection. The researchers suspect that SARS-CoV-2 released from the salivary glands may inhibit the production of antibodies and, as a result, increase the risk of relapse or reinfection. They also could limit the long-term effects of vaccines. Moreover, there was a delay in diagnosis, surgery, chemotherapy, radiation therapies, and oncology follow-ups conducted by telemedicine rather than in-person appointments during this difficult period.

Moreover, traveling to clinics can increase social contact, making these patients more prone to SAR-CoV-2 infection than the general population, which can better quarantine at home. As a result of the COVID-19 pandemics&#39; reduced access to care, the work-up process has slowed even more. There has been a significant decrease in the number of urgent referrals. Furthermore, because of the pandemics and rapid progression in the months following its emergence, physicians and hospitals quickly respond to the crisis and establish a recovery plan to address patient diagnosis and management challenges.

<h3>Salivary Gland Cancer Treatment Market Segment Analysis</h3>

Surgery segment is expected to hold the largest market share in salivary gland cancer treatment market

The surgery segment is expected to dominate in 2021. Surgery is usually the first treatment option for nearly everyone diagnosed with salivary gland cancer. The goal of surgery is to remove as much of the tumor as possible while keeping the margins as clean as possible. It signifies that no trace of cancer is identified in the removed healthy tissue. Cancer&#39;s location and extent determine the type and scope of surgery.

Moreover, many types of surgery are used to treat salivary gland cancer&mdash;for instance, Parotidectomy, Endoscopic surgery, Neck dissection, and Reconstructive surgery. Therefore, it has increased the demand for the treatment. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Salivary Gland Cancer Treatment Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type,&nbsp;By Diagnosis,&nbsp;By Treatment,&nbsp;By End-User,&nbsp;By Distribution Channel, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

<h3>Salivary Gland Cancer Treatment Market Geographical Analysis</h3>

North America region holds the largest market share in the global salivary gland cancer treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of salivary gland cancer, the rising geriatric population, advancements in the treatment, well-established infrastructure and product launches by the key players are some factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, Salivary gland cancers are not very common, making up 6% to 8% of all head and neck cancers in the United States. There are about 2,000 to 2,500 cases in the US each year. They occur at about 3 cases per 100,000 people per year in the Western world.

Moreover, using drugs to kill cancer cells is known as systemic treatment. This sort of drug is injected into the bloodstream to reach cancer cells all over the body. A medical oncologist, a clinician, specializing in using medications to treat cancer, usually prescribes systemic therapy. The benefits of systemic therapy for salivary gland cancer are still being researched, and this sort of treatment is being tested in clinical studies. In addition, Systemic therapy is most commonly used to treat later-stage cancer or to reduce symptoms in patients with salivary gland cancer. Some medications are being tested in clinical trials to see if they can treat cancer at an earlier stage or be paired with radiation therapy to see if it works. Therefore, it has increased the demand for the treatment of salivary gland cancer. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

<h3>Salivary Gland Cancer Treatment Market Competitive Landscape</h3>

Major key players in the salivary gland cancer treatment market are Bristol-Myers Squibb Company, LGM PHARMA, Pfizer Inc., Bedford Laboratories, Baxter, sanofi-aventis U.S. LLC, Pierre Fabre M&eacute;dicament, Antares Pharma, Inc., CMS Group, Sandoz Inc.&nbsp;&nbsp;&nbsp; &nbsp;

Bristol Myers Squibb:

Overview:

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company. It is headquartered in New York City. The company has advancements in oncology, hematology, immunology and cardiovascular disease. It is dedicated to helping patients prevail over serious diseases through its diverse and promising pipelines and new scientific platforms. Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines. Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs and is a subsidiary of Bristol Myers Squibb.

&shy;Product Portfolio:

PLATINOL (cisplatin for injection): Platinol (cisplatin) for Injection is a cancer medication used together with other medications to treat various types of cancers.

<h3>MyLab&trade;9V</h3>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>Visualize the composition of the salivary gland cancer treatment market segmentation by type, diagnosis, treatment, end user, distribution channel and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in salivary gland cancer treatment market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of salivary gland cancer treatment market- level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global salivary gland cancer treatment market report would provide an access to an approx. 45+market data table, 40+figures and 200 pages.

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Diagnosis</li>
		<li>Market Snippet by Treatment</li>
		<li>Market Snippet by End user</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing clinical trials and product launches by the market players are expected to drive market growth.</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Lack of awareness about the disorder is expected to hamper in the forecast period.</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>By Type
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type Segment</li>
		</ol>
		</li>
		<li>Mucoepidermoid Carcinoma*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Adenoid Cystic Carcinoma</li>
		<li>Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma)</li>
		<li>Polymorphous adenocarcinoma</li>
		<li>Pleomorphic Adenoma</li>
		<li>Warthin&rsquo;s Tumor</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Diagnosis
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Attractiveness Index, By Diagnosis Segment</li>
		</ol>
		</li>
		<li>Physical exam*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Imaging tests
		<ol>
			<li>Magnetic resonance imaging (MRI)</li>
			<li>Computerized tomography (CT)</li>
			<li>Positron emission tomography (PET)</li>
			<li>Ultrasound</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Biopsy</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Treatment
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Attractiveness Index, By Treatment Segment</li>
		</ol>
		</li>
		<li>Surgery*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Radiation therapy</li>
		<li>Chemotherapy
		<ol>
			<li>Cisplatin</li>
			<li>Mitoxantrone</li>
			<li>Doxorubicin (Adriamycin)</li>
			<li>Epirubicin (Ellence)</li>
			<li>Cyclophosphamide (Cytoxan)</li>
			<li>Paclitaxel (Taxol)</li>
			<li>Docetaxel (Taxotere)</li>
			<li>Vinorelbine (Navelbine)</li>
			<li>Methotrexate</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Supportive (palliative) care</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By End user
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Attractiveness Index, By End user Segment</li>
		</ol>
		</li>
		<li>Hospital*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Clinics</li>
		<li>Ambulatory Surgical Centers</li>
		<li>Diagnostic Centers</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>Hospital Pharmacy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacy</li>
		<li>Online Pharmacy</li>
		<li>Others</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>List of Key Companies to Watch</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Bristol-Myers Squibb Company*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview &nbsp;</li>
		</ol>
		</li>
		<li>LGM PHARMA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Pfizer Inc.&nbsp;&nbsp;</li>
		<li>Bedford Laboratories&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Baxter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>sanofi-aventis U.S. LLC&nbsp;</li>
		<li>Pierre Fabre M&eacute;dicament&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>Antares Pharma, Inc.&nbsp;&nbsp;&nbsp;&nbsp;</li>
		<li>CMS Group&nbsp;</li>
		<li>Sandoz Inc.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Applications</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table1 Global Salivary Gland Cancer Treatment Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table2 Global Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2021, 2025 &amp; 2029 ($ Million)

Table3 Global Salivary Gland Cancer Treatment Market Value, By Treatment, 2021, 2025 &amp; 2029 ($ Million)

Table4 Global Salivary Gland Cancer Treatment Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)

Table5 Global Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table6 Global Salivary Gland Cancer Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table7 Global Salivary Gland Cancer Treatment Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table8 Global Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table9 Global Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2021, 2025 &amp; 2029 ($ Million)

Table10 Global Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table11 Global Salivary Gland Cancer Treatment Market Value, By Treatment, 2021, 2025 &amp; 2029 ($ Million)

Table12 Global Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table13 Global Salivary Gland Cancer Treatment Market Value, By End user, 2021, 2025 &amp; 2029 ($ Million)

Table14 Global Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table15 Global Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table16 Global Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table17 Global Salivary Gland Cancer Treatment Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table18 Global Salivary Gland Cancer Treatment Market Value, By Region, 2020-2029 ($ Million)

Table19 North America Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table20 North America Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table21 North America Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table22 North America Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table23 North America Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table24 North America Salivary Gland Cancer Treatment Market Value, By Country, 2020-2029 ($ Million)

Table25 South America Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table26 South America Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table27 South America Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table28 South America Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table29 South America Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table30 South America Salivary Gland Cancer Treatment Market Value, By Country, 2020-2029 ($ Million)

Table31 Europe Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table32 Europe Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table33 Europe Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table34 Europe Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table35 Europe Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table36 Europe Salivary Gland Cancer Treatment Market Value, By Country, 2020-2029 ($ Million)

Table37 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table38 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table39 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table40 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table41 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table42 Asia-Pacific Salivary Gland Cancer Treatment Market Value, By Country, 2020-2029 ($ Million)

Table43 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, By Type, 2020-2029 ($ Million)

Table44 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, By Diagnosis, 2020-2029 ($ Million)

Table45 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, By Treatment, 2020-2029 ($ Million)

Table46 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, By End user, 2020-2029 ($ Million)

Table47 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table48 Bristol-Myers Squibb Company: Overview

Table49 Bristol-Myers Squibb Company: Product Portfolio

Table50 Bristol-Myers Squibb Company: Key Developments

Table51 LGM PHARMA: Overview

Table52 LGM PHARMA: Product Portfolio

Table53 LGM PHARMA: Key Developments

Table54 Pfizer Inc.: Overview

Table55 Pfizer Inc.: Product Portfolio

Table56 Pfizer Inc.: Key Developments

Table57 Bedford Laboratories: Overview

Table58 Bedford Laboratories: Product Portfolio

Table59 Bedford Laboratories: Key Developments

Table60 Baxter: Overview

Table61 Baxter: Product Portfolio

Table62 Baxter: Key Developments

Table63 sanofi-aventis U.S. LLC: Overview

Table64 sanofi-aventis U.S. LLC: Product Portfolio

Table65 sanofi-aventis U.S. LLC: Key Developments

Table66 Pierre Fabre M&eacute;dicament: Overview

Table67 Pierre Fabre M&eacute;dicament: Product Portfolio

Table68 Pierre Fabre M&eacute;dicament: Key Developments

Table69 Antares Pharma, Inc.: Overview

Table70 Antares Pharma, Inc.: Product Portfolio

Table71 Antares Pharma, Inc.: Key Developments

Table72 CMS Group: Overview

Table73 CMS Group: Product Portfolio

Table74 CMS Group: Key Developments

Table75 Sandoz Inc.: Overview

Table76 Sandoz Inc.: Product Portfolio

Table77 Sandoz Inc.: Key Developments

List of Figures

Figure1 Global Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure2 Global Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure3 Global Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure4 Global Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure5 Global Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure6 Global Salivary Gland Cancer Treatment Market Share, By Region, 2020 &amp; 2029 (%)

Figure7 Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure8 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By Type, 2020-2028 (%)

Figure9 Mucoepidermoid Carcinoma: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure10 Adenoid Cystic Carcinoma: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure11 Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma): Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure12 Polymorphous adenocarcinoma: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure13 Pleomorphic Adenoma: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure14 Warthin&rsquo;s Tumor: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure15 Others: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure16 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By Diagnosis, 2020-2028 (%)

Figure17 Physical exam: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure18 Imaging tests: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure19 Biopsy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure20 Others: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure21 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By Treatment, 2020-2028 (%)

Figure22 Surgery: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure23 Radiation therapy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure24 Chemotherapy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure25 Supportive (palliative) care: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure26 Others: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure27 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By End user, 2020-2028 (%)

Figure28 Hospitals: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure29 Clinics: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure30 Ambulatory Surgical Centers: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure31 Diagnostic Centers: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure32 Others: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure33 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By Distribution Channel, 2020-2028 (%)

Figure34 Hospital Pharmacy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure35 Retail Pharmacy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure36 Online Pharmacy: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure37 Others: Global Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure38 Global Salivary Gland Cancer Treatment Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure39 North America Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure40 North America Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure41 North America Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure42 North America Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure43 North America Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure44 North America Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure45 North America Salivary Gland Cancer Treatment Market Share, By Country, 2020 &amp; 2029 (%)

Figure46 South America Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure47 South America Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure48 South America Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure49 South America Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure50 South America Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure51 South America Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure52 South America Salivary Gland Cancer Treatment Market Share, By Country, 2020 &amp; 2029 (%)

Figure53 Europe Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure54 Europe Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure55 Europe Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure56 Europe Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure57 Europe Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure58 Europe Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure59 Europe Salivary Gland Cancer Treatment Market Share, By Country, 2020 &amp; 2029 (%)

Figure60 Asia-Pacific Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure61 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure62 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure63 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure64 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure65 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure66 Asia-Pacific Salivary Gland Cancer Treatment Market Share, By Country, 2020 &amp; 2029 (%)

Figure67 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Value, 2020-2029 ($ Million)

Figure68 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Share, By Type, 2020 &amp; 2029 (%)

Figure69 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Share, By Diagnosis, 2020 &amp; 2029 (%)

Figure70 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Share, By Treatment, 2020 &amp; 2029 (%)

Figure71 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Share, By End user, 2020 &amp; 2029 (%)

Figure72 Middle East &amp; Africa Salivary Gland Cancer Treatment Market Share, By Distribution Channel, 2020 &amp; 2029 (%)

Figure73 Bristol-Myers Squibb Company: Financials

Figure74 LGM PHARMA: Financials

Figure75 Pfizer Inc.: Financials

Figure76 Bedford Laboratories: Financials

Figure77 Baxter: Financials

Figure78 sanofi-aventis U.S. LLC: Financials

Figure79 Pierre Fabre M&eacute;dicament: Financials

Figure80 Antares Pharma, Inc.: Financials

Figure81 CMS Group: Financials

Figure82 Sandoz Inc.: Financials